Autism not diagnosed as early in minority children

WASHINGTON (AP) — Early diagnosis is considered key for autism, but minority children tend to be diagnosed later than white children. Some new work is beginning to try to uncover why — and to raise awareness of the warning signs so more parents know they can seek help even for a toddler.

"The biggest thing I want parents to know is we can do something about it to help your child," says Dr. Rebecca Landa, autism director at Baltimore's Kennedy Krieger Institute, who is exploring the barriers that different populations face in getting that help.

Her preliminary research suggests even when diagnosed in toddlerhood, minority youngsters have more severe developmental delays than their white counterparts. She says cultural differences in how parents view developmental milestones, and how they interact with doctors, may play a role.

Consider: Tots tend to point before they talk, but pointing is rude in some cultures and may not be missed by a new parent, Landa says. Or maybe mom's worried that her son isn't talking yet but the family matriarch, her grandmother, says don't worry — Cousin Harry spoke late, too, and he's fine. Or maybe the pediatrician dismissed the parents' concern, and they were taught not to question doctors.

It's possible to detect autism as early as 14 months of age, and the American Academy of Pediatrics recommends that youngsters be screened for it starting at 18 months. While there's no cure, behavioral and other therapies are thought to work best when started very young.

Yet on average, U.S. children aren't diagnosed until they're about 4½ years old, according to government statistics.

And troubling studies show that white kids may be diagnosed with autism as much as a year and a half earlier than black and other minority children, says University of Pennsylvania autism expert David Mandell, who led much of that work. Socioeconomics can play a role, if minority families have less access to health care or less education.

But Mandell says the full story is more complex. One of his own studies, for example, found that black children with autism were more likely than whites to get the wrong diagnosis during their first visit with a specialist.

At Kennedy Krieger, Landa leads a well-known toddler treatment program and decided to look more closely at those youngsters to begin examining the racial and ethnic disparity. She found something startling: Even when autism was detected early, minority children had more severe symptoms than their white counterparts.

By one measure of language development, the minority patients lagged four months behind the white autistic kids, Landa reported in the Journal of Autism and Developmental Disorders.

It was a small study, with 84 participants, just 19 of whom were black, Asian or Hispanic. But the enrolled families all were middle class, Landa said, meaning socioeconomics couldn't explain the difference.

One of the study's participants, Marlo Lemon, ignored family and friends who told her not to worry that her son Matthew, then 14 months, wasn't babbling. Boys are slower to talk than girls, they said.

"I just knew something was wrong," recalls Lemon, of Randallstown, Md.

Her pediatrician listened and knew to send the family to a government "early intervention" program that, like in most states, provides free testing and treatment for young children's developmental delays. Matthew was enrolled in developmental therapy by age 18 months, and was formally diagnosed with autism when he turned 2 and Lemon enrolled him in Kennedy Krieger's toddler program as well. In many of his therapy classes, Lemon says, Matthew was the only African-American.

Now 7, Matthew still doesn't speak but Lemon says he is making huge strides, learning letters by tracing them in shaving cream to tap his sensory side, for example, and using a computer-like tablet that "speaks" when he pushes the right buttons. But Lemon quit working full-time so she could shuttle Matthew from therapy to therapy every day.

"I want other minority families to get involved early, be relentless," says Lemon, who now works part-time counseling families about how to find services early.

For a campaign called "Why wait and see?" Landa is developing videos that show typical and atypical behaviors and plans to ask Maryland pediatricians to show them to parents. Among early warning signs:

—Not responding to their name by 12 months, or pointing to show interest by 14 months.

—Avoiding eye contact, wanting to play alone, not smiling when smiled at.

—Saying few words. Landa says between 18 and 26 months, kids should make short phrases like "my shoe" or "where's mommy," and should be adding to their vocabulary weekly.

—Not following simple multi-step commands.

—Not playing pretend.

—Behavioral problems such as flapping their hands or spinning in circles.

___

EDITOR's NOTE — Lauran Neergaard covers health and medical issues for The Associated Press in Washington.

View original post here:
Autism not diagnosed as early in minority children

The umbilical cord blood stem cells break new ground in healing hard-to-cure diseases – Video

28-10-2011 21:43 [Anchor] With the increasing number of the patients who suffer from the hard-to-cure diseases, various treatments have been tried for eliminating the cause. Recently, the "umbilical cord blood stem cells" are brought up to be the new solutions and give hope to the patients. Our next report has the details. [Reporter] The stem cells are basic cells for making about two hundred and sixty of body cells such as bones, bloods, and nerves. By duplicating themselves, the stem cells restore the damaged cells. Among them, especially, the umbilical cord blood stem cells are highly effective on curing the hard-to-cure diseases. Those cells, which have the functions to investigate and chase the specific cells, are from the cellular tissue of the umbilical cord. With this, it is possible to load the anti-cancer genes or healing substances so as to fight off the germs selectively. [Interview - Won-il Oh, Director of Research of MEDIPOST] ~ The umbilical cord blood stem cells go inside of the body and find the affected area with specific disease. It is used for curing the incurable diseases like stroke, brain tumor and arthritis. The "umbilical cord blood stem cell therapy products" regenerate the cells and tissues that are damaged from diseases. Since the products are made from the adult stem cells extracted from the cord blood, the differentiation with the existing medicine is expected. Along with this, the number of people who are using the "cord blood bank" has been increasing ...

The rest is here:
The umbilical cord blood stem cells break new ground in healing hard-to-cure diseases - Video

Scientists urged to share data on stem cells research

By Noimot Olayiwola
Staff Reporter
Researchers and scientists in the field of both embryonic and adult stem cells research in the Middle East were yesterday urged to be more open to collaboration and networking among themselves in order to build on their already acquired and existing strengths for the betterment of the future use of stem cells in curing genetic diseases in the region.
Stem cells are ‘unspecialised’ cells that are able to divide and produce copies of themselves and having the potential to differentiate, that is, to produce other cell types in the body.
Speaking on how to further expand the scope of stem cell research in the region during a panel discussion yesterday at the ongoing Qatar International Conference on Stem Cell Science and Policy, Weill Cornell Medical College in Qatar’s Dr Jeremie Arash Rafii Tabrizi said there was the need for the region’s researchers in the field of stem cells to know each other and come together to network and form collaborations.
“I believe that each and everyone in the field within this region has built some sort of strength while conducting their individual researches, so I will suggest that we all come together to put heads together and also explore how we can benefit from our colleagues elsewhere. And if we can be more diseases-focused in our researches, I believe it is a good way to move forward,” he noted.
Making a presentation on “Stem Cell Research: From Promise to Practice”, Dr Aida al-Aqeel, of Riyadh Military Hospital’s paediatrics department, maintained that it would take a while before stem cell research can become a ‘clinical reality’.
“Despite that stem cell research is at the forefront of the need for research to cure most degenerative diseases, it will still take a long way for the stem cell research to become achievable clinically because the embryonic stem cells (ESCs) have huge therapeutic potential as they can give rise to every cell type in the body (pluripotency) as compared to adult stem cells (ASCs) from certain adult tissues that can only differentiate into a limited range of cell types,” she said.
“However, this research raises sensitive ethical and religious arguments, which are balanced against possible great benefit of such research for the patients suffering from so far incurable diseases. Serious questions remain about safety,” she said, noting that the ability for stem cells to be expanded in culture without genetic and epigenetic abnormalities and their ability to form functional cell types in vitro and in vivo, and their immuno-compatibility with the patient still need to be studied.
“In Saudi Arabia, for the last five years, the Stem Cell Therapy Programme has been established at King Faisal Specialist Hospital and Research Centre with the launch of 10 projects. Embryonic stem cell therapy for genetics metabolic disorders is one of the most promising modalities for the therapy and prevention of mentally and physically handicapped in children,” she said while sharing experiences from the KSA.
She pointed out how Islamic teachings make embryonic stem cell research and therapeutic technique, and its modality of treatment permissible as well as the Islamic perspectives about reproductive/therapeutic cloning.
“The focus of research community should be on developing human research capacity in both ASCs and ESCs. Each type of research will take time to mature. The ethical debate will need to produce acceptable policy and regulatory compromises so that the regulatory burden can be reduced and investors’ risk aversion can be overcome,” she stated.
Other speaker during the session moderated by WCMC-Q dean Dr Javaid Sheikh were Professor Hossein Baharvand from the Royan Institute for Reproductive Biomedicine Stem Cell Biology and Technology on “A Chemical Approach to Efficient Generating Embryonic and Germline-derived Pluripotent Stem Cells”.

Continue reading here:
Scientists urged to share data on stem cells research

Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.

In the preclinical studies conducted by leading scientists including Professors Melamed and Offen of Tel Aviv University and originally reported in Experimental Neurology, patients' bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) that were transplanted into an animal model of Huntington disease showed therapeutic benefits.

Addressing the role of these MSC-NTF cells in Huntington disease, Professor Daniel Offen explains, "the premise is that such cells can be transplanted safely into affected areas of the brain, and thereby serve as vehicles for delivering neurotrophic factors." Offen expressed his hope that this cell-based therapy may eventually progress to the clinic.

BrainStorm is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results have shown that Brainstorm’s NurOwn™ therapy is safe, does not show any significant treatment-related adverse events, and have also shown certain signs of beneficial clinical effects.

Follow this link for the Research Highlights page in Nature Reviews Neurology (starts Feb. 28th ): http://www.nature.com/nrneurol/journal/vaop/ncurrent/index.html

To read the Original Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. follow this link: http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot (www.ramot.org) at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

More here:
Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

Nature: BrainStorm’s NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.

In the preclinical studies conducted by leading scientists including Professors Melamed and Offen of Tel Aviv University and originally reported in Experimental Neurology, patients' bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) that were transplanted into an animal model of Huntington disease showed therapeutic benefits.

Addressing the role of these MSC-NTF cells in Huntington disease, Professor Daniel Offen explains, "the premise is that such cells can be transplanted safely into affected areas of the brain, and thereby serve as vehicles for delivering neurotrophic factors." Offen expressed his hope that this cell-based therapy may eventually progress to the clinic.

BrainStorm is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results have shown that Brainstorm’s NurOwn™ therapy is safe, does not show any significant treatment-related adverse events, and have also shown certain signs of beneficial clinical effects.

Follow this link for the Research Highlights page in Nature Reviews Neurology (starts Feb. 28th ): http://www.nature.com/nrneurol/journal/vaop/ncurrent/index.html

To read the Original Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. follow this link: http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot (www.ramot.org) at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

More here:
Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

Seminar to focus on stem cell research development

The latest discoveries and promises of stem cell research and the development of new therapeutic approaches for a variety of diseases will be in focus at the Qatar International Conference on Stem Cell Science and Policy 2012 which begins today.
The four-day event, being held at Qatar National Convention Centre, is a milestone in Qatar Foundation’s ongoing collaboration with the James A Baker III Institute for Public Policy at Rice University, Houston, Texas, US.
The aim of QF’s joint initiative with the Baker Institute’s International Programme on Stem Cell Science Policy is to develop stem cell research in Qatar as well as to find ways to address the shared challenges of community support for stem cell research in Doha and Houston.
To accomplish this goal, the programme has supported several events since its inception, including meetings, workshops, and training programmes in both cities.
The conference, which brings together eminent international as well as regional scientists, ethicists and policymakers, will also present the developed policy options that account for cultural, ethical and religious factors.
The event will draw attention to Qatar’s position in the development of stem cell research in the region and the world, given that research on stem cell as a national priority has already been initiated in the country’s best research institutions.
The conference objectives are to raise the awareness about Qatar’s initiative in promoting stem cell research, present the latest developments, and highlight the different religious views regarding stem cell research specifically the Islamic view.
The pros and cons of various options for regulating stem cell research and how scientists should address conflicting and confusing national policies and assess the different models of international collaboration will be discussed.
The conference also intends to interface with other institutions outside Qatar and contribute to the exchange of scientific knowledge to enhance the promotion of a scientific culture in the region and globally.
The keynote speakers are ambassador Edward P Djerejian (Baker Institute), Irving Weissman (Stanford University), Alan Trounson (president, California Institute for Regenerative Medicine), David Baltimore (president emeritus, Robert Andrews Millikan Professor of Biology, California Institute of Technology), Roger Pedersen (Department of Surgery, University of Cambridge) and Lawrence Corey (president and director, Fred Hutchinson Cancer Research Centre).
The conference, supported by Qatar Biomedical Research Institute, will also feature a number of invited speakers from across the world.

Read more from the original source:
Seminar to focus on stem cell research development

Stem cell fertility treatments could be risky for older women

Harvard scientists are challenging traditional medical logic that dictates that women are born with a finite amount of eggs.  The scientists said they have discovered the ovaries of young women harbor rare stem cells that are in fact capable of producing new eggs.

If properly harnessed, those stem cells may someday lead to new treatments for women suffering from infertility due to cancer or other diseases – or for those who are simply getting older, according to the researchers.  Lead researcher Jonathan Tilly of Harvard's Massachusetts General Hospital has co-founded a company, OvaScience Inc., to try to develop the findings into fertility treatments.

The idea that women are born with all the egg cells – called oocytes – they’ll ever have has been called into question by past research, which found egg-producing stem cells in adult mice.

In this latest study, Harvard researchers, in collaboration with Japanese scientists, used donated frozen ovaries from 20 year olds and ‘fished out’ the purported stem cells.  

The researchers inserted a gene into the stem cells, which caused them to glow green.  If the cells produced eggs, those would glow green, too.

The researchers first watched through a microscope as new eggs grew in a lab dish.  They then implanted the human tissue under the skin of mice to provide a nourishing blood supply.  Within two weeks, they observed green-tinged cells forming.

While the work of the Harvard scientists does show potential, there are still questions as to whether the cells are capable of growing into mature, usable eggs.

If so, researchers said, it might be possible one day to use the stem cells in order to grow eggs in lab dishes to help preserve cancer patients’ fertility, which can be harmed by chemotherapy.

Now, I just want to say, while this would be a remarkable discovery – if it pans out – I do have a few concerns. 

I think for specific patients in prime, childbearing ages, who are at risk of losing their fertility for one reason or another, this could be a fruitful discovery for them.

Be that as it may, I am totally against commercializing this technology to the point where women going through menopause look at this as another way of getting pregnant.  For many, this could create incredibly high-risk pregnancies, among other medical problems.

While science is capable of great discovery and innovation – particularly in the field of stem cells – I believe that with reproductive medicine, we should move forward with great caution to minimize any risk to mother and baby.

Continued here:
Stem cell fertility treatments could be risky for older women

An Editorial on Telomeres and Longevity

Telomeres are the ends of the chromosome, caps of repeating DNA sequences that shorten with each cell division and lengthen according to the activity of the enzyme telomerase - this is a very dynamic process, responding differently to circumstances in different cells and tissue types. Telomere length somewhat acts as a countdown clock, moving a cell towards shutdown after a certain number of divisions rather than permitting continued replication, but as for all matters biological the telomere-telomerase-chromosome system considered as a whole is exceedingly complex. It influences and is influenced by many other important cellular systems and feedback loops: mitochondrial damage, for example, appears tied to telomere length and telomerase activity. Thus even as data rolls in ever faster in this age of biotechnology, the telomere story has stubbornly remained that telomeres generally become shorter on average with age or ill health or stress, and that this shortening might be a contribution to aging or it might only be a marker for other cellular changes and damage that occurs with aging.

This is an important distinction to draw: we should find ways to fix and reverse the changes that are fundamental, that are causes of aging. But we don't have to fix and reverse the markers and secondary changes. If we repair the root causes, the many other line items should take care of themselves. But biology is complicated - obtaining the answers for processes that are right down there in the depths of the cellular machinery, central to everything and touching on everything, takes time.

Here's a good editorial from Impact Aging, very readable for the layperson:

Not surprisingly, given that species differ in many other relevant aspects of their biology, including the pattern of activity of the telomere-restoring enzyme telomerase simple comparisons of average telomere length across species do not map directly onto interspecific variation in maximum lifespan. In relatively long-lived species, telomerase is downregulated in most somatic cells, thought to have evolved as a mechanism to counteract an increased risk of tumour formation, particularly in endotherms. One potential cost of this is that tissue renewal capacity is limited, resulting in somatic deterioration with age.

However, within a given long-lived species, there is good reason to predict that variation in average telomere length in somatic cells will be related to potential lifespan. Examining this link is fraught with difficulties, not least of which is that studies covering the entire lifespan of a cohort of long lived animals take a very long time. Circumventing this by looking at telomere length and subsequent survival in individuals that are already old omits all the individuals who died early in life (and who may have had the shortest telomeres). The alternative approach of comparing average telomere length in a cross sectional sample of individuals of different ages suffers from a related bias; mean telomere length could actually appear to increase with age if individuals with short telomeres die and so drop out of the sample. Furthermore, since telomere length is a dynamic character, if it is predictive of lifespan, we also need to know at what life history stage the relationship is strongest. Longitudinal studies are therefore essential.

Time is the most precious thing for us, and it is unfortunate that finding the necessary information that would allow the research community to be more effective in addressing the causes of aging - by eliminating potential mechanisms from the "must fix" list - might at this point take up more time than it would save.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Considering Identity

Philosophy determines strategy - it matters greatly which of the answers to the fundamental existential questions you subscribe to. Consider questions of identity, for example: do you identify with the pattern that is you, or do you identify with the present slowly changing collection of physical structure that is you? If the former, you might consider destructively uploading the data of your mind to a robust computing system to be a fine strategy for the defeat of aging. If the latter, destructive uploading looks like an expensive and ornate suicide method - you are not your copy, and you will not survive the procedure. Doors to the future open or close depending on your philosophical inclinations. Here's a piece that reviews some of the spectrum of philosophical thinking on identity, which has been going on for a good deal longer than modern ideas and technologies have been around: "Star Trek-style teleportation may one day become a reality. You step into the transporter, which instantly scans your body and brain, vaporizing them in the process. The information is transmitted to Mars, where it is used by the receiving station to reconstitute your body and brain exactly as they were on Earth. You then step out of the receiving station, slightly dizzy, but pleased to arrive on Mars in a few minutes, as opposed to the year it takes by old-fashioned spacecraft. But wait. Do you really step out of the receiving station on Mars? Someone just like you steps out, someone who apparently remembers stepping into the transporter on Earth a few minutes before. But perhaps this person is merely your replica - a kind of clone or copy. That would not make this person you: in Las Vegas there is a replica of the Eiffel Tower, but the Eiffel Tower is in Paris, not in Las Vegas. If the Eiffel Tower were vaporized and a replica instantly erected in Las Vegas, the Eiffel Tower would not have been transported to Las Vegas. It would have ceased to exist. And if teleportation were like that, stepping into the transporter would essentially be a covert way of committing suicide."

Link: http://www.bostonreview.net/BR37.1/alex_byrne_philosophy_personal_identity_afterlife.php

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Variant of LMNA Associated With Survival to Old Age

Via Extreme Longevity: "Progeria is a rare disease in which children age very rapidly, acquire diseases of the elderly and typically die in teenage years with the phenotypical appearance of the elderly. The disease has been found to occur due to mutations in the LMNA gene which codes for the nuclear envelope proteins called lamin-A and lamin-B. These proteins are responsible for the security and integrity of the nuclear membrane surrounding the cell's DNA. When these proteins are mutated the DNA is poorly protected and quickly and extensively damaged leading to accelerated aging. In this study the researchers hypothesized that just as certain single nucleotide polymorphisms (SNPs or mutations) cause individuals with progeria to age rapidly, perhaps other variants of the gene would protect people from aging and lead to extreme longevity. To test this hypothesis, the researchers compared 16 SNP variants of the LMNA gene in persons over age 95 versus genetically matched younger controls. They detected a specific 4-SNP variation of the gene appeared to be more frequent in the elderly. They then looked for the presence of this haplotype in several other genetic databases of centenarians and again found a higher frequency than chance of the same mutation. The authors concluded 'these results suggest that LMNA variants may play a role in human lifespan.'"

Link: http://extremelongevity.net/2012/02/22/nuclear-lamin-gene-found-associated-with-extreme-human-longevity/

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Another Demonstration of Extended Longevity in Mice through Transplantation of Stem Cells

A couple of years ago, Chinese researchers demonstrated modestly extended longevity in mice through transplantation of mesenchymal stem cells. This sort of thing is a very brute-force approach to enhanced regeneration: it's more or less the least and first possible action that can be taken after developing the technology to extract, purify, and culture stem cells outside the body. Researchers are still in the midst of gathering a full understanding of what exactly goes on under the hood in the variety of circumstances and methodologies whereby tissue is flooded with additional stem cells. But as is demonstrated by the trials and stem cell clinics around the world, there is ample evidence that benefits are possible given the right approach.

Here is a more recent open access paper by a different research group that also shows extended longevity in mice with transplantation of stem cells; in this case cells from young donor mice given to old recipient mice:

Increasing evidence suggests that the loss of functional stem cells may be important in the aging process. Our experiments were originally aimed at testing the idea that, in the specific case of age-related osteoporosis, declining function of osteogenic precursor cells might be at least partially responsible.

To test this, aging female mice were transplanted with mesenchymal stem cells from aged or young male donors. We find that transplantation of young mesenchymal stem cells significantly slows the loss of bone density and, surprisingly, prolongs the life span of old mice. These observations lend further support to the idea that age-related diminution of stem cell number or function may play a critical role in age-related loss of bone density in aging animals and may be one determinant of overall longevity.

...

The mean life span of control mice was 765 days However, the mean life span for mice that received young BMSCs transplants was 890 days ... Overall, these results suggest that transplantation of BMSCs derived from young animals extends life span. However, it is not clear whether the prolonged lifespan may be associated with improved tissue regeneration.

The connection between attempting therapy for osteoporosis and resulting increases in longevity have shown up in other contexts - such as that bisphosphonate study that was reported a year ago or so - enough to make it a possible point of interest, and something to keep an eye out for in future research results. There's certainly no shortage of research groups working on osteoporosis or other bone issues with the use of mesenchymal stem cells. For example:

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

SIRT6 and Mouse Longevity

An article on recent sirtuin research - while extended longevity is demonstrated, I don't think it changes the big picture on sirtuins all that much: "Mammals, including humans, have seven types of sirtuins, called SIRT1 to SIRT7. Scientists aren't sure what these proteins do, although there is some evidence suggesting that they might help prevent chronic diseases such as cancer and cardiovascular disease. For example, resveratrol, the nutrient found in grape skins (and red wine), has been shown to have a positive effect on heart health, and it may work by activating the SIRT1 gene to make more SIRT1 protein. The Israeli researchers, led by Yariv Kanfi, focused on SIRT6. The team's previous work revealed that mice genetically bred to have lots of SIRT6 could get fat on rich diets yet show no signs of heart disease, fatty liver disease and other diseases associated with obesity. Previous research by other groups showed that mice genetically bred to have little SIRT6 don't live very long. And, conversely, rats living longer on a calorie-restricted diet have increased levels of SIRT6 in their blood. So, this time the Israeli team simply decided to let the SIRT6 mice live a natural life. These male mice lived longer, about 16 percent longer on average, than regular mice kept in the same conditions. The female mice with the SIRT6 gene enhancement didn't live longer than regular mice. The researchers speculate that, considering how male mice have a higher rate of cancers compared with the females, the SIRT6 could be acting as a tumor suppressor and thus have a larger effect on male life span than female life span."

Link: http://news.yahoo.com/anti-aging-protein-extends-life-span-mice-maybe-180802189.html

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Interesting Hypothesis on Eye Aging

A novel viewpoint is outlined in this article, though as always it remains to be seen how important the effect is in comparison with other concrete manifestations of aging: "For decades, scientists have looked for explanations as to why certain conditions occur with age, among them memory loss, slower reaction time, insomnia and even depression. They have scrupulously investigated such suspects as high cholesterol, obesity, heart disease and an inactive lifestyle. Now a fascinating body of research supports a largely unrecognized culprit: the aging of the eye. The gradual yellowing of the lens and the narrowing of the pupil that occur with age disturb the body's circadian rhythm, contributing to a range of health problems, these studies suggest. As the eyes age, less and less sunlight gets through the lens to reach key cells in the retina that regulate the body's circadian rhythm, its internal clock. ... Circadian rhythms are the cyclical hormonal and physiological processes that rally the body in the morning to tackle the day's demands and slow it down at night, allowing the body to rest and repair. This internal clock relies on light to function properly, and studies have found that people whose circadian rhythms are out of sync, like shift workers, are at greater risk for a number of ailments, including insomnia, heart disease and cancer. ... We believe that it will eventually be shown that cataract surgery results in higher levels of melatonin, and those people will be less likely to have health problems like cancer and heart disease"

Link: http://www.nytimes.com/2012/02/21/health/aging-of-eyes-is-blamed-in-circadian-rhythm-disturbances.html

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

The Goals for Stem Cell Medicine Ultimately Include Repair of Aging

The long term goals for the field of stem cell medicine tend to come back around to include rejuvenation at some point. It's unavoidable, really: the medical conditions most obviously suited to treatment via stem cell therapies are the malfunctions and disrepair of old age - failing muscles, hearts, livers, and other more complex organs. But stem cell populations and their supporting infrastructure in the body also fail right at the time when they are most needed. (That progressive failure of stem cell capacity with age goes some way to causing the time of greatest need, of course, but it's far from the whole story of degenerative aging). The bottom line is that to ensure effectiveness for stem cell treatments in the old, efforts must be made to reverse the aging of their stem cells and the aging of stem cell support systems in the body.

You might recall the research group that demonstrated reversal of some aspects of stem cell aging in mice by introducing young blood into old animals - and vice versa, illustrating that the changes of aging observed in stem cells are due at least as much the environment within the body as to the cells themselves. Those scientists been working on the aging of stem cells for some years now, tracing mechanisms and looking for key biochemical switches; here is a piece that outlines their view of the future:

Unlike stem cells in the blood or skin, muscle stem cells spend most of their lives nestled in the surrounding tissue. "They don't do much most of the time," said Rando. "They remain in a quiescent state for most of a person's life. When you injure your muscle, however, they begin dividing to repair the damage. ... Although on the surface the quiescent state seems to be relatively static, it's quite actively maintained. We've found that changing the levels of just one specific microRNA in resting muscle stem cells, however, causes them to spring into action."

...

If you're going to use muscle stem cells as a therapy for disease or aging, you want to be able to transplant cells that have the greatest potential to make new muscle in the recipient. The quiescent state most closely resembles how they are in the body. If you allow them to divide in the lab before transplantation, they are not as effective. This microRNA may allow us to toggle the cells back and forth between the actively dividing and quiescent states.

...

In the future, the researchers will continue to look at the unique features of quiescent muscle stem cells, including those involved in normal aging. "We'd like to understand the aging process at a very fundamental level," said Rando. "That will allow us to move toward more therapeutic applications. Can we use what we've learned to convert old stem cells, which seem to have lost their responsiveness to activation cues, into young stem cells? Maybe the ability of old stem cells to exit the quiescent state is defective. We may one day be able to develop approaches that enhance tissue repair by enhancing stem cell function."

Paired with increasingly effective early detection and elimination of cancer, it should be very feasible in the years ahead to postpone the decline of stem cells in the body. That decline appears to exist as a mechanism to reduce the risk of cancer, but if cancer as a worrying condition becomes a thing of the past there's no reason for us not to dial our stem cells back up to full potency to maintain our tissues better and for longer.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Another Line of Nerve Regeneration Research

A look at ongoing work on nerve regeneration in one laboratory: "One technology used [by] neurosurgeons is the NeuraGen Nerve Guide, a hollow, absorbable collagen tube through which nerve fibers can grow and find each other. The technology is often used to repair nerve damage over short distances less than half an inch long. ... [Researchers] compared several methods to try to bridge a nerve gap of about half an inch in rats. The team transplanted nerve cells from a different type of rat into the wound site and compared results when the NeuraGen technology was was used alone or when it was paired with [dorsal root ganglion neurons, or DRG cells], or with other cells known as Schwann cells. After four months, the team found that the tubes equipped with either DRG or Schwann cells helped bring about healthier nerves. In addition, the DRG cells provoked less unwanted attention from the immune system than the Schwann cells, which attracted twice as many macrophages and more of the immune compound interferon gamma. While both Schwann and DRG cells are known players in nerve regeneration, Schwann cells have been considered more often as potential partners in the nerve transplantation process, even though they pose considerable challenges because of the immune system's response to them. ... In a related line of research, [scientists] are creating DRG cells in the laboratory by stretching them, which coaxes them to grow about one inch every three weeks. The idea is to grow nerves several inches long in the laboratory, then transplant them into the patient, instead of waiting months after surgery for the nerve endings to travel that distance within the patient to ultimately hook up."

Link: http://www.urmc.rochester.edu/news/story/index.cfm?id=3415

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Printing Muscle at Organovo

From the Methuselah Foundation blog: "A thin layer of human skeletal muscle is being printed by Chirag Khatiwala in a small, sterile room of San Diego-based startup Organovo. Each muscle cell from the company's signature 3-D printer is uniformly deposited in closely spaced lines on a petri dish. This allows the cells to grow and interconnect until they form working muscle tissue nearly indistinguishable from a human muscle biopsy. Unlike other experimental approaches that utilize ink-jet printers to deposit cells, Organovo's technology enables cells to interact with each other the way they do in the body. How? They are packed tightly together, sandwiched, if you will, and incubated. This prompts them to cleave to each other and interchange chemical signals. When printed, the cells are grouped together in a paste that helps them grow, migrate, and align themselves properly. In the case of muscle cells, the way they orient themselves in the same direction allow for contractions of the tissue. ... Methuselah Foundation honors the efforts of Organovo through early funding and support as well as through its new, highly anticipated New Organ Mprize. The true prize is elevated health and quality of life for those that have had to or will suffer the blows of a failing organ. Every $10 helps us work in tandem with today's stunningly advanced technology so that at some tomorrow, no one will have to suffer or die because of a diseased organ."

Link: http://blog.mfoundation.org/2012/02/_fantastical_scenes_from_the.html

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Aubrey de Grey and Max More will be Speaking at the BIL Unconference in March

This year's BIL unconference will be held on March 3rd, on the Queen Mary in Long Beach, California.

BIL is an ad-hoc conference for people changing the world in big ways. It's a place for passionate people to come together to energize, brainstorm, and take action. ... Most of you have heard of TED or watched the talks online, but do you know about BIL, the quirky, populist, unconference taking place nearby? Open to the public and fully participant powered, BIL features a wild mix of technologists, scientists, artists, hackers, and those with a passion for community awareness.

Amongst those scheduling themselves to speak are Aubrey de Grey of the SENS Foundation and Max More of Alcor:

De Grey's research focuses on whether regenerative medicine can thwart the aging process. He works on the development of what he calls "Strategies for Engineered Negligible Senescence" (SENS), a tissue-repair strategy intended to rejuvenate the human body and allow an indefinite lifespan. To this end, he has identified seven types of molecular and cellular damage caused by essential metabolic processes. SENS is a proposed panel of therapies designed to repair this damage.

...

Max More is an internationally acclaimed strategic philosopher widely recognized for his thinking on the philosophical and cultural implications of emerging technologies. ... At the start of 2011, he became President and CEO of the Alcor Life Extension Foundation, the world's leading cryonics organization. ... Max will give a fresh perspective on cryonics as a bridge to an indefinitely extended life.

You'll find some other familiar faces in the list of participants, some of whom are also quite active in the longevity science advocacy community.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Regular vitamin and mineral supplementation lowers colon can

by: John Phillip

Researchers publishing in the Canadian Journal of Physiology and Pharmacology (CJPP) have found that a diet enhanced with vitamin and mineral supplementation can lower the risk of developing precancerous colon cancer lesions by up to 84%. Colon cancer is the second most common form of the disease affecting men and women in the US, with nearly 150,000 new diagnoses each year.

Nutrition experts and alternative practitioners understand that cancer is largely a disease caused by poor lifestyle behaviors including a diet lacking an optimal intake of vitamins and minerals. Chronic illnesses including colon cancer are the result of many years and decades of low nutritional status, as support for a healthy immune response is suppressed. Scientists now provide compelling evidence in support of whole-food based vitamin and mineral supplementation to dramatically lower the risk of colorectal cancer. Read more...

AyurGold for Healthy Blood

Source:
http://feeds.feedburner.com/integratedmedicine

The Afterlife of the California Stem Cell Agency: Venture Philanthropy and Big Pharma


The $3 billion California stem cell agency, which is facing its possible demise in five years, is exploring an afterlife that dips into "venture philanthropy" on a national level as well as investment ties with Big Pharma.

The Golden State's unprecedented research program laid out those possibilities in a "transition plan" sent this week to Gov. Jerry Brown and the state legislature. The plan was required under a law passed two years ago. The agency's future direction was also aired at a meeting last month in Los Angeles.

The California Institute for Regenerative Medicine(CIRM) will run out of funds for new grants in 2017. Its only real source of funding is cash that the state borrows (bonds). CIRM says that only $864 million remains for new research awards, and some of its recent grant rounds exceed $200 million. The current position of the agency is that it is "premature" to consider asking voters in financially strapped California to approve another multi-billion dollar bond measure.

The venture philanthropy effort involves creation of a nonprofit organization. CIRM Chairman Jonathan Thomas said in January that he is "test-driving (the proposal) with some high net worth donors we know to be interested in the stem cell space." Thomas was addressing the Citizens Financial Accountability and Oversight Committee, the only state entity specified charged with overseeing the agency and its directors. He said,

"We're busily putting together in conjunction with a national organization called the Alliance for Regenerative Medicine the plans for a nonprofit venture philanthropy fund."

He said it would "would accept applications for awards from researchers and companies all over the country, not just those funded by CIRM, but those funded by NIH or the New York Stem Cell Foundation or the state of Maryland or whatever."

The Alliance for Regenerative Medicine is an industry-dominated lobbying group, based in Washington, D.C.  The group's executive director and co-founder is Michael Werner, a longtime pharma and health industry lobbyist, who is also a partner in the influential Washington law firm of Holland and Knight.

The "biopharma investment fund" proposed by CIRM is less well developed. CIRM said it plans to explore opportunities with companies to fund stem cell research in California. The transition document uses as an example an $85 million deal between Pfizer and UC San Francisco, which gives the company special access to biomedical research.

The transition plan also touches on other issues such as winding down grants after its new grant money runs out, along with protecting intellectual property.

The plan could be considered a marketing tool for the agency's afterlife efforts. The document devotes a good portion of its nine pages to recounting the history of CIRM and touting its accomplishments.

Thomas used the occasion of the submission of the plan as a springboard for a piece yesterday on the CIRM research blog.He concluded his item by quoting from the plan itself. CIRM's achievements during the past seven years, he wrote, "will allow California to continue world (stem cell) leadership in the coming decades."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

IOM's Lagging Effort for Comments on the $3 Billion California Stem Cell Agency


With the $700,000 Institute of Medicine inquiry into the performance of the California stem cell agency half complete – at least publicly – the blue-ribbon panel seems to be coming up short on comments from outside of the agency itself.

The major public effort by the IOM to secure comments is the passive posting of forms to be filled out on the IOM web site.

How many responses has the IOM received on those forms? The IOM has not disclosed that information despite two inquiries earlier this month by the California Stem Cell Report.

The prestigious institute is undertaking the study of $3 billion agency under contract with CIRM, which is paying the IOM $700,000. Some CIRM directors have expressed hope that the IOM findings will help build support for another multi-billion dollar state bond measure to renew financing for CIRM. It is scheduled to run out of money for new grants in five years.

So far, the IOM panel has held two public meetings, one in Washington, D.C., and one in the San Francisco area. The final California hearing is scheduled for April 10 in Irvine with the last public meetings scheduled for later this year in Washington.

So far, the panel has heard only from CIRM employees or directors as well as researchers who have received tens of millions of dollars in CIRM grants. The IOM has not heard publicly from a single independent witness.

The IOM has posted on its web site forms seeking comments from the public, grant recipients, beneficiary institutions and businesses. However, passive postings of forms are unlikely to generate more than a relative handful of responses. To produce significant numbers requires aggressive and targeted follow-up.

It is also unclear exactly what the IOM is doing to seek information from biotech businesses and unsuccessful grant applicants. Some businesses have complained publicly about the tiny share of funding that industry has received. And some CIRM directors have expressed concern for several years about the inadequacies of business funding.

On Feb. 12, the California Stem Cell Report queried the IOM about its efforts at outreach, asking for specifics on what is being done. Christine Stencel, a spokeswoman for the IOM, replied,

"The IOM has been obtaining and compiling lists of organizations and people to circulate the questionnaires as widely as possible among target groups. For example, IOM has sent a notice to some 300 stakeholder groups encouraging participation."

Other specifics were not forthcoming. (The full text of the questions and responses can be found here.)

On Feb. 15, the California Stem Cell Report followed up with these additional questions,

"Regarding the 300 stakeholder groups, how are those defined? Please give me a few examples.

"Based on your response, is it correct to say that the IOM is not sending out questionnaires directly to all CIRM grant applicants, including those who were rejected?

"Is it correct to say that no special effort -- other than that described in your response -- is being made to seek responses from stem cell businesses?

"The failure to provide numbers on the responses so far would indicate that the numbers are so small that the IOM is choosing not to disclose them. If that is not the case, please email me the numbers."

As of this writing, the IOM has not responded to those questions. We will carry its response verbatim when we receive it.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss